Pharmaceuticals, Biotechnology and Life Sciences
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was…
SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel…
BOSTON, June 20, 2025 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025…
KUALA LUMPUR, June 20, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that…
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of…
WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global…
Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDTBALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE)…
Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and…
TORONTO, June 20, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology…
GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a…